Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2024. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through wholly-owned subsidiary Leonard-Meron Biosciences, Inc. and majority-owned subsidiaries Citius Oncology, Inc. (CTOR) and NoveCite, Inc. In August 2024, Citius Oncology became a publicly traded company via a reverse merger, with Citius Pharma retaining a 92.3% ownership interest. The company received FDA approval for its oncology product LYMPHIR in August 2024 but has not yet generated commercial revenue.
Key Financial Metrics
| Metric | Q1 2025 (Ended Dec 31, 2024) | Q1 2024 (Ended Dec 31, 2023) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,281,246) | $(9,231,185) |
| Net Loss Per Share (Basic/Diluted) | $(1.30) | $(1.45) |
| Operating Expenses | $10,039,614 | $9,340,823 |
| Cash and Cash Equivalents | $1,100,079 | $20,345,618 |
| Working Capital | $(26.5 million) | Not explicitly stated |
| Net Cash Used in Operating Activities | $(4,725,852) | $(6,135,310) |
Balance Sheet Highlights: Total assets were $120.7 million, driven by $92.8 million in in-process research and development (IPR&D) and $14.4 million in inventory (primarily LYMPHIR). Total liabilities were $51.8 million, including $28.4 million in license payables and $7.4 million in accounts payable.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by approximately $700,000 year-over-year. General and administrative (G&A) expenses increased by $1.7 million to $5.4 million, primarily due to pre-launch sales and marketing activities for LYMPHIR. Conversely, R&D expenses decreased by $495,000 to $2.1 million, reflecting the completion of Phase 3 trials for Mino-Lok and reduced costs for Halo-Lido.
- Significant Cash Burn: Cash and cash equivalents declined by $2.15 million during the quarter, dropping from $3.25 million to $1.1 million. This contrasts with the prior year period where cash balances were significantly higher ($26.5 million at the start of the period).
- Stock-Based Compensation: Stock-based compensation expense decreased by $533,000 to $2.5 million, largely due to lower costs associated with the Citius Pharma stock plans.
- Capital Raise: The company executed a registered direct offering in November 2024, raising net proceeds of $2.57 million.
Outlook, Risks, and Management Commentary
- Going Concern Uncertainty: Management has raised substantial doubt about the company's ability to continue as a going concern. With cash reserves of approximately $1.1 million, the company estimates it can fund operations only through March 2025.
- Liquidity Strategy: The company is actively engaged in capital raise initiatives, including a registered direct offering in January 2025 (raising approx. $3.0 million gross) and an At-The-Market (ATM) offering. Future operations depend on raising additional capital or generating revenue from LYMPHIR sales.
- Commercialization: The company expects to begin commercial sales of LYMPHIR in 2025. Inventory of $14.4 million consists of finished goods and work-in-process for LYMPHIR.
- Commitments: The company has significant future obligations, including a $22.5 million milestone payment to Dr. Reddy's (partially deferred) and $5.9 million to Eisai. Additionally, there are minimum purchase commitments of approximately $21.8 million for commercial manufacturing through 2026.
- Reverse Stock Split: A 1-for-25 reverse stock split was effective November 25, 2024, to regain compliance with Nasdaq listing requirements.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 million cash balance against the stated March 2025 runway and the status of ongoing fundraising efforts.
- License Payables: Confirm the payment schedule and deferral terms for the $28.4 million in license payables, specifically the $22.5 million owed to Dr. Reddy's.
- LYMPHIR Commercialization: Assess the timeline for the first commercial sale of LYMPHIR and the associated revenue recognition, which is critical for amortizing the $92.8 million IPR&D asset.
- Manufacturing Commitments: Review the $21.8 million in minimum purchase commitments for manufacturing and packaging to ensure they align with projected sales volumes.
- Subsequent Equity Dilution: Monitor the impact of the January 2025 registered direct offering and ATM sales on share count and dilution.